181 completed, 99 unknown, 36 recruiting, 33 terminated. 207 Phase 2, 146 Phase 3, 37 Phase 1, 20 Not applicable, 12 Phase 4.
Follow this drug Literature Review of Epirubicin trials Research Report on Epirubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids Epirubicin, Mitomycin, Gemcitabine - Bladder Cancer, Non-muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Hospital Centre Biel/Bienne | 28 | 2026-12-01 | 2026-09-18 |
| Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma Golidocitinib, Doxorubicin, Epirubicin - Nodal T-follicular Helper Cell Lymphoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 47 | 2026-08-15 | 2026-08-07 |
| Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC Active Surveillance, Adjuvant Intravesical Chemotherapy - Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC) | Not applicable | Recruiting | Tianjin Medical University Second Hospital | 670 | 2026-08-10 | 2026-10-09 |
| Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study Epirubicin and cyclophosphamide followed by paclitaxel oral solution - Triple -Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | Liu Shu | 30 | 2026-07-30 | 2026-08-04 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic Carcinoma Anlotinib + Epirubicin - Adenoid Cystic Carcinoma | Phase 2 | Not yet recruiting | Eye & ENT Hospital of Fudan University | 76 | 2026-06-01 | 2026-06-01 |
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study Epirubicin (E) - Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 100 | 2026-01-20 | 2026-05-12 |
| Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC Biospecimen Collection, Breast Biopsy Procedure, Carboplatin - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Recruiting | Vandana Abramson | 51 | 2025-09-09 | 2025-10-30 |
| Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) nab-paclitaxel, carboplatin, and bemotuzumab, epirubicin, cyclophosphamide, and bemotuzumab - Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy | Not applicable | Not yet recruiting | Zhejiang Provincial People's Hospital | 55 | 2025-09-01 | 2025-05-22 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2400 | 2025-06-30 | 2026-10-13 |
| Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer Serplulimab, Epirubicin, Albumin Paclitaxel - HR+/HER2- Breast Cancer | Phase 2 | Recruiting | Henan Cancer Hospital | 357 | 2025-04-15 | 2026-08-19 |
| A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) Pembrolizumab, Paclitaxel, Carboplatin - Early Triple Negative Breast Cancer | Phase 2 | Withdrawn | Merck Sharp & Dohme LLC | 2025-03-26 | 2026-02-19 | |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) Patritumab deruxtecan, Pembrolizumab, Paclitaxel - Breast Neoplasms, Breast Cancer | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 372 | 2025-03-20 | 2026-09-10 |
| Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer Cyclophosphamide, Epirubicin, Docetaxel - Triple Negative Breast Cancer | Phase 2 | Recruiting | University of Chicago | 85 | 2025-03-18 | 2026-02-17 |
| Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer HIFU, Toripalimab, nab-Paclitaxel (nab-P) - ER+/HER2- Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 30 | 2025-03-04 | 2026-07-14 |
| Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients Docetaxel plus cyclophosphamide, Epirubicin, cyclophosphamide plus paclitaxel - Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Fudan University | 1462 | 2025-02-01 | 2025-01-28 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. HS-20093, Anlotinib, Epirubicin - Osteosarcoma, Soft Tissue Sarcoma (STS) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 448 | 2024-12-20 | 2024-11-21 |
| Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide - Breast Cancer | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 48 | 2024-11-01 | 2025-06-26 |
Showing 20 of 395. Sign in to see all of them.
Breast Neoplasms (211) · Triple Negative Breast Neoplasms (33) · Stomach Neoplasms (32) · Inflammatory Breast Neoplasms (21) · Esophageal Neoplasms (16) · Carcinoma, Hepatocellular (15) · Lymphoma, Large B-Cell, Diffuse (9) · Neoplasms (8) · Sarcoma (8) · Adenocarcinoma Of Esophagus (7) · Non-Muscle Invasive Bladder Neoplasms (7) · Urinary Bladder Neoplasms (6) · Breast Neoplasms, Male (5) · Liver Neoplasms (5) · Pancreatic Neoplasms (5)
Fudan University (18) · GBG Forschungs GmbH (11) · UNICANCER (11) · Chinese Academy of Medical Sciences (8) · Hellenic Oncology Research Group (8) · Henan Cancer Hospital (8) · Hoffmann-La Roche (8) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (8) · M.D. Anderson Cancer Center (7) · Shanghai Jiao Tong University School of Medicine (7) · Merck Sharp & Dohme LLC (6) · Hebei Medical University Fourth Hospital (5) · Sun Yat-sen University (5) · Cancer Trials Ireland (4) · European Organisation for Research and Treatment of Cancer - EORTC (4)
China (122) · United States (64) · Germany (45) · France (41) · United Kingdom (41) · Italy (40) · Spain (29) · Belgium (22) · Canada (21) · Sweden (16) · Switzerland (16) · Poland (15) · South Korea (14) · Taiwan (14) · Hungary (13)
Dimitris Mavrudis, MD (7) · Michele Reni, MD (4) · Norman Wolmark, MD (4) · Yanyan Liu, M.D. Ph.D (4) · Helena Earl, MBBS, PhD, FRCP (3) · David Cunningham (2) · Denise A. Yardley, MD (2) · Ding Xiaowen, DR. (2) · Edith A. Perez, MD (2) · Erwei Song, M.D., Ph.D. (2) · Gunnar B. Kristensen, MD, PhD (2)
PMID 34037241, PMID 38979716, PMID 22508812, PMID 34252375, PMID 16757203, PMID 17960615, PMID 21612974, PMID 32450725, PMID 37097003, PMID 37338729, PMID 40207789, PMID 10076722, PMID 10207464, PMID 10458221, PMID 11181777, PMID 12049862, PMID 12594571, PMID 12623635, PMID 12893895, PMID 14656276, PMID 15967833, PMID 16293863, PMID 16305946, PMID 16421418, PMID 16822992, PMID 16939953, PMID 17664469, PMID 17877488, PMID 18024211, PMID 18037940, PMID 18224661, PMID 18332648, PMID 18355796, PMID 18572266, PMID 18650156, PMID 18768436, PMID 18797468, PMID 18852074, PMID 18952561, PMID 19104202, PMID 19241423, PMID 19304921, PMID 19453695, PMID 19468030, PMID 19560026, PMID 19771508, PMID 19917839, PMID 19926229, PMID 20037779, PMID 20060288
2016 (5), 2005 (3), 2008 (3), 2014 (3), 2009 (2), 2023 (2), P30CA072720 (2), U10CA012027 (2), 2017 (1), 2018 (1), K23CA121994 (1), P30CA008748 (1), P30CA015083 (1), P30CA016672 (1), P30CA036727 (1)